Which country is durvalumab/Infinifer manufactured in?

Durvalumab/Durvalumab is an innovative drug that has attracted much attention in the field of tumor immunotherapy in recent years. Its original research company is the internationally renowned pharmaceutical giant AstraZeneca AB. As a multinational pharmaceutical company, AstraZeneca has invested heavily in the layout of the tumor immunotherapy pipeline, of which durvalumab is a representative product. With its innovative mechanism and exploration of multiple indications, this drug has gradually become an important part of the global immunotherapy field.

Durvalumab is an immune checkpoint inhibitor that helps the immune system identify and attack cancer cells by targeting the PD-L1 pathway. Unlike traditional chemotherapy and radiotherapy, this new type of therapy does not directly kill cancer cells, but restores the body's own anti-tumor ability by lifting immune suppression. Because of this, it has been gradually used in the treatment of a variety of malignant tumors, includingsmall cell lung cancer, non-small cell lung cancer, endometrial cancer, cholangiocarcinoma, liver cancer, bladder cancer, etc. Different types of cancer have differences at the pathological and molecular levels, but they often have commonalities in immune evasion mechanisms, and durvalumab captures this core link and shows its application value across cancer types.

From a global perspective, the development and production of durvalumab embodies AstraZeneca's innovative strength. The drug is not only widely used in developed countries such as Europe and the United States, but also gradually entered the Asian market. For Chinese patients, as imported drugs are gradually included in medical insurance and localized production is promoted, the accessibility of durvalumab continues to increase, bringing new treatment options to more cancer patients. It is worth mentioning that as a drug jointly developed by the United Kingdom and Sweden, its international background also allows clinicians to have more references and evidence-based basis when formulating individualized treatment plans.

Reference materials:https://www.imfinzi.com/